A phase 2 trial tested poziotinib’s efficacy in the treatment of HER-2-overexpressing metastatic breast cancer patients in the third line and beyond, showing meaningful antitumoral efficacy with overall survival benefits and a toxicity profile similar to other TKIs [86,87]. This evidence concerns the gene ERBB2 and breast carcinoma.